$Can-Fite BioPharma (CANF.US)$ According to the data of the American Cancer Society, liver cancer causes more than 0.7 million deaths globally each year. HCC is usually aggressive with low survival rates. With the development and approval of effective and safe HCC new drugs, Delveinsight expects the HCC treatment market in G8 countries to reach 6.1 billion dollars by 2027.

$Can-Fite BioPharma (CANF.US)$ Ramat Gan, Israel, December 4, 2024 (Global News Network) - Can-Fite BioPharma Limited (NYSE: CANF) (Tel Aviv Stock Exchange: CANF) is a biotechnology company advancing proprietary small molecule drug development, focusing on cancer and inflammatory diseases. Today, it announced that in the second phase liver cancer study at Can-Fite, patients currently undergoing treatment with Namodenoson have an overall survival of 8 years in the compassionate use program. One patient, who previously participated in Can-Fite's second phase study and continued treatment with Namodenoson, has an overall survival of 8 years, with ascites disappeared, normal liver function, good quality of life, and defined as long-term complete responder.

$Can-Fite BioPharma (CANF.US)$ 8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Can-Fite's Namodenoson Drug
GlobeNewswire· 9 mins ago

$Cognition Therapeutics (CGTX.US)$ Cognition Therapeutics, Inc. (nasdaq: CGTX) is a clinical-stage company dedicated to developing drugs for the treatment of neurodegenerative diseases, providing an update on the biomarker analysis in the phase 2 'SHINE' study in mild to moderate Alzheimer's disease. This new analysis focuses on plasma samples from all participants entering the study with low levels of plasma P-t217. Several blood-based measurements of Alzheimer's disease biology were normalized in the CT1812 treatment group compared to the placebo group. These biomarker changes are consistent with a 95% slowing in cognitive decline measured by ADAS-Cog11 in the same patients. These data further demonstrate that CT1812 may maintain cognitive function and slow disease progression by protecting critical neural systems.

$Vast Renewables (VSTE.US)$
Vast Renewables Ltd: Signed an Updated Funding Agreement to Access up to $30 Mln of Its Existing $65 Mln Grant From Arena

$DevvStream (DEVS.US)$ I won't buy in because of too much debt.

$SKK Holdings (SKK.US)$
Too many people are trapped.

$SKK Holdings (SKK.US)$ I still encourage you to go $Virpax Pharmaceuticals (VRPX.US)$ 🤣

Just can't seem to win here. Got stop loss and woke up to this $SKK Holdings (SKK.US)$